Dr Reddy’s launches insomnia treatment tablets in US
The company has launched Ramelteon tablets in the strength of 8 mg after getting approval from USFDA
Drug major Dr Reddy’s Laboratories has said it has launched generic Ramelteon tablets used for treatment of insomnia in the US market. The company has launched Ramelteon tablets in the strength of 8 mg after getting approval from the United States Food and Drug Administration (USFDA), Dr Reddy’s said in a BSE filing.
The product is a generic version of Takeda Pharmaceutical’s Rozerem tablets in the same strength, it added. The Rozerem brand had the US sales of around $91.3 million MAT (moving annual total) for the most recent 12 months ending in May 2019, Dr Reddy’s said.
The company’s generic 8 mg Ramelteon tablets are available in bottle count sizes of 30, 100 and 1,000, it added. The tablets are indicated for the treatment of insomnia characterised by difficulty with sleep onset.